Alumis Inc. has provided an updated corporate presentation detailing advancements in its TYK2 inhibitor programs, envudeucitinib and A-005. The company is focusing on significant market opportunities projected to exceed $180 billion across various indications. Envudeucitinib has shown highly significant efficacy in moderate-to-severe plaque psoriasis, with leading PASI 100 responses and early improvements in quality of life and symptoms. Key upcoming milestones include additional psoriasis data and an NDA filing for envudeucitinib in Q4 2026, and topline data from the Phase 2b LUMUS trial for Systemic Lupus Erythematosus (SLE) in Q3 2026. The A-005 program, a CNS-penetrant TYK2 inhibitor, is set to initiate a Phase 2 biomarker trial in Parkinson's disease in 1H 2027. The company reported $569.5 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with a cash runway expected into Q4 2027.